Co-Diagnostics (CODX) Projected to Post Earnings on Tuesday

Co-Diagnostics (NASDAQ:CODX) will likely be issuing its Q4 2025 results after the market closes on Tuesday, March 31st. Analysts expect the company to announce earnings of ($3.90) per share and revenue of $0.1260 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:30 PM ET.

Co-Diagnostics Trading Down 12.0%

CODX opened at $2.28 on Tuesday. The firm’s 50 day simple moving average is $2.57 and its two-hundred day simple moving average is $7.76. The company has a market capitalization of $4.78 million, a PE ratio of -0.08 and a beta of 1.31. Co-Diagnostics has a 1-year low of $2.05 and a 1-year high of $46.50.

Hedge Funds Weigh In On Co-Diagnostics

A number of hedge funds have recently modified their holdings of CODX. Geode Capital Management LLC increased its stake in shares of Co-Diagnostics by 40.4% in the fourth quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock worth $81,000 after purchasing an additional 129,158 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Co-Diagnostics by 314.1% during the 2nd quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock valued at $47,000 after buying an additional 126,105 shares in the last quarter. Finally, Virtu Financial LLC lifted its stake in shares of Co-Diagnostics by 393.8% during the 3rd quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock valued at $44,000 after buying an additional 100,901 shares in the last quarter. 14.99% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on CODX shares. HC Wainwright restated a “neutral” rating on shares of Co-Diagnostics in a research note on Monday, November 24th. Wall Street Zen upgraded Co-Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Maxim Group lowered Co-Diagnostics from a “buy” rating to a “hold” rating in a report on Friday, January 23rd. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $55.00.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.